ライフサイエンスコーパス: lamivudine

1 zidovudine plus lamivudine, or abacavir plus lamivudine).

2 ibitors (tenofovir/emtricitabine or abacavir/lamivudine).

3 cardiovascular event, all of which involved lamivudine.

4 + G), and all had previously been exposed to lamivudine.

5 first-line antiviral agents are superior to lamivudine.

6 selected tenofovir-emtricitabine or abacavir-lamivudine.

7 All of them were successfully treated with Lamivudine.

8 Each reactivation was treated with Lamivudine.

9 nz, with tenofovir/emtricitabine or abacavir/lamivudine.

10 e antiviral prophylaxis strategy is lifelong lamivudine.

11 induction therapy with dolutegravir-abacavir-lamivudine.

12 fficient for establishing resistance against lamivudine.

13 enofovir disoproxil fumarate or abacavir and lamivudine.

14 84V mutant in the presence of etravirine and lamivudine.

15 nown as EFV400), combined with tenofovir and lamivudine.

16 olerability than dolutegravir, abacavir, and lamivudine.

17 r alafenamide to dolutegravir, abacavir, and lamivudine.

18 or continued oral cabotegravir plus abacavir-lamivudine.

19 relative to oral cabotegravir plus abacavir-lamivudine.

20 sus coformulated dolutegravir, abacavir, and lamivudine.

21 n in those given dolutegravir, abacavir, and lamivudine (10% [n=32] vs 23% [n=72]; p<0.0001).

22 sults available, 195 (82%) had resistance to lamivudine, 128 (54%) to tenofovir, and 219 (92%) to efa

23 daily) or efavirenz (600 mg each night) plus lamivudine 150 mg and zidovudine 300 mg twice daily (or

24 f lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice daily.

25 r (2 RCTs; 600 patients) and HBeAg loss with lamivudine (2 RCTs; 318 patients).

26 deoxy-5-fluoro-3'-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3'-dideoxy-3'-thiacytidine, (-)-3TC]

27 The most common 2DRs were dolutegravir plus lamivudine (22.8%) and raltegravir plus boosted darunavi

28 namide than with dolutegravir, abacavir, and lamivudine (26% [n=82] vs 40% [n=127]), the difference b

29 ted dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg (the dolutegravir group), each with ma

30 s given with efavirenz 600 mg once a day and lamivudine 300 mg once a day.

31 ted dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg once daily.

32 ted dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg, with matching placebo, once daily for

33 y group, n = 69) or combined with zidovudine/lamivudine 300/150 mg twice daily (triple therapy group,

34 wo-drug regimen of dolutegravir (50 mg) plus lamivudine (300 mg) or a once-daily three-drug regimen o

35 ipants with resistance to both efavirenz and lamivudine, 32 (35.6%) of whom were still prescribed the

36 ned to receive efavirenz, both with abacavir-lamivudine; 322 (70%) and 324 (70%), respectively, compl

37 hanges; all levels increased with zidovudine/lamivudine (3TC) and abacavir/3TC (except triglycerides,

38 M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance and

39 M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance, and

40 ypersusceptibility to the nucleoside analogs lamivudine (3TC) and tenofovir at both the virus and enz

41 andomized trial compared abacavir (ABC) plus lamivudine (3TC) and ZDV+3TC as part of a dual or triple

42 omes of children given zidovudine (ZDV) plus lamivudine (3TC) as a 2-drug PEP regimen.

43 ity induce the appearance of proviruses with lamivudine (3TC) drug resistance-associated mutations be

44 herapy (ART) based-on tenofovir (TDF) and/or lamivudine (3TC) in a real-world setting.

45 The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults

46 7 days of life to prophylaxis with LPV/r or lamivudine (3TC) to prevent transmission during breastfe

47 , and stable regimen with DTG/abacavir (ABC)/lamivudine (3TC) were 1:1 randomized to continue their r

48 nd HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritonavir (LPV/r), were

49 ofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Pois

50 AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC), and the nucleotide RTI inhibitor tenof

51 Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricit

52 (RT) inhibitors, such as entecavir (ETV) and lamivudine (3TC), serve as crucial anti-HBV drugs.

53 mized to receive sdNVP and either zidovudine/lamivudine (3TC), tenofovir/emtricitabine (FTC), or lopi

54 e 5 most common NRTI pairs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (d4T)/

55 ith the reverse transcriptase (RT) inhibitor lamivudine (3TC).

56 of dual therapy with dolutegravir (DTG) and lamivudine (3TC).

57 population after switching to abacavir (ABC)/lamivudine (3TC)/DTG over 6 months.

58 cy of 1 or more TDF-containing regimens: TDF/lamivudine (3TC)/nevirapine (NVP) (n = 3), TDF/ emtricit

59 or the triphosphate forms of antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) pro

60 iphosphate (L-dCTP), or the triphosphates of lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) wit

61 sphates of chain-terminating antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP), we

62 9%; 95% CI, 90.2%-97.7%) and lowest for ZDV+ lamivudine [3TC]+LPV/r (59.1%; 95% CI, 36.2%-82.0%).

63 ARD and DRIVE-AHEAD from the DOR groups (DOR/lamivudine [3TC]/tenofovir disoproxil fumarate [TDF] or

64 atives of (-)-2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC, 1) were synthesized and evaluated for t

65 ed with AZT (Zidovudine 100 mg/kg/day), 3TC (Lamivudine 50 mg/kg/day) or D4T (Stavudine 10 mg/kg/day)

66 ceived oral cabotegravir 30 mg plus abacavir-lamivudine 600-300 mg once daily.

67 Subjects received DTG (50 mg) plus abacavir/lamivudine (600/300 mg) once daily.

68 ily treatment with DTG (50 mg) plus abacavir-lamivudine (600/300 mg).

69 re ten with resistance to both tenofovir and lamivudine, 8 (80.0%) of whom were prescribed these drug

70 Five HAART drugs (ritonavir, indinavir, lamivudine, abacavir, and AZT) significantly decreased e

71 Five other HAART drugs (indinavir, lamivudine, abacavir, AZT, and ddI) and the 3-plex signi

72 Lamivudine, abacavir, zidovudine, emtricitabine, and ten

73 transcriptase inhibitor (NRTI) backbone with lamivudine/abacavir (3TC/ABC) as a commonly used alterna

74 oproxil fumarate (FTC/TDF) in P007; abacavir/lamivudine (ABC/3TC) or FTC/TDF in DRIVE-FORWARD; and 3T

75 en-label ATV/r or EFV combined with abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC

76 Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/

77 ficiency virus-infected subjects to abacavir-lamivudine (ABC/3TC) versus tenofovir DF-emtricitabine (

78 enofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).

79 ing of HIV antivirals (stavudine, tenofovir, lamivudine, acyclovir, and zidovudine) was analyzed with

80 s with a low barrier to resistance are used (lamivudine, adefovir).

81 ation with tenofovir disoproxil fumarate and lamivudine after initiation of RIF (10 mg/kg/day).

82 blished pilot study of 1-year treatment with lamivudine/alpha interferon (IFN-alpha) were investigate

83 , and telbivudine offer greater potency than lamivudine and adefovir dipivoxil.

84 survey highlights the impact of exposure to lamivudine and adefovir on development of drug resistanc

85 De-novo combination of lamivudine and adefovir reduces the rate of antiviral re

86 stance mutation N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations V173L, L180

87 was to evaluate the virological responses to lamivudine and emtricitabine in recommended cART.

88 of E138K together with M184I, which confers lamivudine and emtricitabine resistance in most patients

89 ency virus type 1 (HIV-1) infection consider lamivudine and emtricitabine to be interchangeable compo

90 The virological responses to lamivudine and emtricitabine were compared by multivaria

91 stablished although L-deoxycytidine analogs (lamivudine and emtricitabine) and L-thymidine (telbivudi

92 Although lamivudine and emtricitabine, two L-deoxycytidine analog

93 DP, or the diphosphates and triphosphates of lamivudine and emtricitabine.

94 relevant for settings with extensive use of lamivudine and for settings where generic lamivudine wil

95 The antiretrovirals were zidovudine/lamivudine and nelfinavir or lopinavir/ritonavir.

96 xed-dose-combination paediatric tablets with lamivudine and nevirapine or efavirenz.

97 isoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transmission of resistance to t

98 e incidence of birth defects associated with lamivudine and tenofovir use during pregnancy is not inc

99 Exposure to lamivudine and to lamivudine-stavudine were also associa

100 A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the ris

101 sufficient for high-level resistance to both lamivudine and zidovudine in HIV-2, and the combination

102 prophylaxis (lopinavir-ritonavir plus either lamivudine and zidovudine or emtricitabine and tenofovir

103 l drugs (abacavir, acyclovir, emtricitabine, lamivudine and zidovudine) via both bio- and phototransf

104 tratified by prior and/or concomitant use of lamivudine and/or emtricitabine.

105 nation antiretroviral therapy that contained lamivudine and/or tenofovir.

106 The long-term studies of lamivudine (and adefovir) show a consistent reduction in

107 mide, and 315 to dolutegravir, abacavir, and lamivudine) and 645 in study 2 (327 to bictegravir, emtr

108 l fumarate and emtricitabine or abacavir and lamivudine) and with no resistance were randomized to co

109 us tenofovir-emtricitabine or tenofovir plus lamivudine), and D (best available NRTIs plus ritonavir-

110 ing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir; and an estimated glomerular fi

111 ve, the benefits of transition to tenofovir, lamivudine, and dolutegravir for all substantially outwe

112 le on ART, including switching to tenofovir, lamivudine, and dolutegravir in those currently on ART,

113 ted with use of a policy in which tenofovir, lamivudine, and dolutegravir is used in all people on AR

114 initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine or ritonavir-boosted l

115 iral therapy (DAART) for HIV/HBV (tenofovir, lamivudine, and emtricitabine) in a large cohort encompa

116 drugs (efavirenz, tenofovir, emtricitabine, lamivudine, and indinavir), only efavirenz increased ER

117 mtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovudine-based AR

118 ed to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and

119 ents on the first-line regimen of stavudine, lamivudine, and nevirapine the benefits of viral load or

120 recommended first-line regimen of stavudine, lamivudine, and nevirapine to second-line antiretroviral

121 ; ARR, 1.31; 95% CI, 1.13-1.52); zidovudine, lamivudine, and NPV (ZDV-3TC-NVP) (647 of 1365 [47.4%];

122 d vaccination alone; the use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnanc

123 pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decrease cost but may re

124 Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly associated

125 One of these-efavirenz, lamivudine, and zidovudine-was the second most commonly

126 after the virologic failure of rilpivirine-, lamivudine-, and emtricitabine-containing regimens.

127 These data support lamivudine as an option for preexposure prophylaxis.

128 The use of emtricitabine instead of lamivudine as part of cART was associated with better vi

129 -Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor

130 (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as a prospective analysis of 76 lami

131 :1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate

132 dons Lys103Asn, Tyr181Cys, Gly190Ala, and to lamivudine at Met184Val, and when at least one drug-resi

133 th co-formulated dolutegravir, abacavir, and lamivudine at week 96.

134 ed with PEG-IFN (some were also treated with lamivudine) at 11 European and Asian hospitals; genotype

135 nd emtricitabine or combination abacavir and lamivudine background treatment.

136 Once generic coformulations of tenofovir/lamivudine become accessible, however, the appropriate p

137 Telbivudine is more potent than lamivudine but is associated with a high rate of antivir

138 than in those given efavirenz with abacavir-lamivudine but not with tenofovir DF-emtricitabine.

139 sistant variants were partially inhibited by lamivudine, but remained fit in its presence.

140 nofovir plus emtricitabine or tenofovir plus lamivudine), C (ritonavir-boosted darunavir plus raltegr

141 In the lamivudine cohort, 11 (6.4%) of 171 cases of HBV recurre

142 o receive didanosine-stavudine or zidovudine-lamivudine, combined with efavirenz and/or nelfinavir.

143 of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/rit

144 reatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possi

145 human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) witho

146 of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppressi

147 Although therapeutic responses to long-term lamivudine-containing HAART were comparable between HIV-

148 The median duration of lamivudine-containing highly active antiretroviral thera

149 Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy

150 nts were randomized 1:1 to continue abacavir/lamivudine/dolutegravir or switch to dolutegravir (MONCA

151 e nucleoside reverse transcriptase inhibitor lamivudine downregulated IFN-I activation and age-associ

152 are active against HBV infection, including lamivudine, emtricitabine, tenofovir, and, more recently

153 in 93% for efavirenz/nevirapine, in 81% for lamivudine/emtricitabine, in 59% for etravirine/rilpivir

154 in vivo study in chimeric mice harboring the lamivudine/entecavir triple mutant, FMCAP effectively re

155 ve demonstrated significant activity against lamivudine/entecavir triple mutants (L180M + S202G + M20

156 uble (rtL180M/rtM204V) mutants as well as in lamivudine/entecavir triple mutants (L180M+S202G+M204V)

157 ine, as well as a prospective analysis of 76 lamivudine-experienced subjects who introduced tenofovir

158 hepatitis B (some nucleoside-naive and some lamivudine-experienced) were randomized 2:1 to receive T

159 enofovir exposure; most were also zidovudine/lamivudine exposed.

160 ors for resistance were age, viral load, and lamivudine exposure (P < .001).

161 r zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group).

162 214 (23%) patients treated with PEG-IFN +/- lamivudine for 52 weeks experienced flares.

163 sitive CHB patients treated with PEG-IFN +/- lamivudine for 52 weeks in a global randomized trial wer

164 uited if they were continuously treated with lamivudine for at least 10 years and maintained favorabl

165 Preventive therapy with lamivudine for patients who test positive for HBsAg and

166 ed nausea in the dolutegravir, abacavir, and lamivudine group (5% [n=17] vs 17% [n=55]; p<0.0001).

167 3 of 315) in the dolutegravir, abacavir, and lamivudine group (difference -0.6%, 95.002% CI -4.8 to 3

168 %) of 315 in the dolutegravir, abacavir, and lamivudine group (difference -2.6%, 95% CI -8.5 to 3.4).

169 verse event was also shorter in the abacavir-lamivudine group (P<0.001).

170 %) of 315 in the dolutegravir, abacavir, and lamivudine group (study 1), and six (2%) of 320 in the b

171 re was significantly shorter in the abacavir-lamivudine group than in the tenofovir DF-emtricitabine

172 57 virologic failures (14%) in the abacavir-lamivudine group versus 26 (7%) in the tenofovir DF-emtr

173 Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effe

174 eron-alpha2a combined with lamivudine versus lamivudine improved HBeAg loss (1 RCT; 543 patients) and

175 Pegylated interferon-alpha2a versus lamivudine improved HBeAg seroconversion (1 RCT; 814 pat

176 Meanwhile, an NRTI, lamivudine, improves insulin sensitivity and reduces inf

177 02, 322 Chinese CHB patients were started on lamivudine in our center.

178 stance have been found with long-term use of lamivudine, in up to 76% of patients treated for 5 years

179 , abacavir, stavudine, didanosine (ddI), and lamivudine] individually or in combination [three HAART

180 tio of virological failure at week 240 using lamivudine instead of emtricitabine was 2.35 (95% CI, 1.

181 Lamivudine is increasingly being used to prevent hepatit

182 al therapy with lopinavir and ritonavir plus lamivudine is non-inferior to standard triple therapy.

183 leoside analog (3TC-TP, triphosphate form of lamivudine) is incorporated slowly, allowing the conform

184 Lamivudine (LAM) has been shown to prevent de novo hepat

185 sion to 40.3% at month 36 (P < 0.001), while lamivudine (LAM) or emtricitabine (FTC) use remained ste

186 hronic hepatitis B patients with preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver tra

187 l data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing he

188 e or in combination with interferon (IFN) or lamivudine (LAM) versus IFN or LAM were included.

189 02, or M250, which emerge in the presence of lamivudine (LVD) resistance substitutions M204I/V +/- L1

190 hibitor (K103N, V106M, Y181C, and G190A) and lamivudine (M184V) resistance mutations were quantified

191 Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen.

192 The majority (73.8%) were exposed to lamivudine monotherapy.

193 mended first-line therapies, and 30% were on lamivudine monotherapy.

194 e rate of antiviral resistance compared with lamivudine monotherapy.

195 ovudine (mother 300 mg; infants 2 mg/kg) and lamivudine (mothers 150 mg; infants 4 mg/kg) twice a day

196 cleoside reverse transcriptase inhibitor and lamivudine mutations present at >2% of the viral populat

197 = 128) or switch to darunavir/ritonavir and lamivudine (n = 129).

198 or coformulated dolutegravir, abacavir, and lamivudine (n=315), of whom 314 and 315 patients, respec

199 amide (n=316) or dolutegravir, abacavir, and lamivudine (n=315).

200 Genotyping and drug concentrations (lamivudine, nevirapine, and efavirenz) were measured on

201 in were associated with failure of stavudine-lamivudine-nevirapine (d4T/3TC/NVP; P < .01), and K103N,

202 hs in HIV-positive adults starting stavudine/lamivudine/nevirapine in Malawi, using Sanger, deep, clo

203 first-line regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.69; 2.49-17

204 lamivudine (PI group) or abacavir/zidovudine/lamivudine (NRTI group) in a clinical trial to prevent m

205 Treatment with lamivudine of patients infected with hepatitis B virus (

206 et regimen of dolutegravir plus abacavir and lamivudine once a day (dolutegravir group) or a three-ta

207 olutegravir at a dose of 50 mg plus abacavir-lamivudine once daily (DTG-ABC-3TC group) or combination

208 i-HBV regimens were TDF/emtricitabine (57%), lamivudine or emtricitabine (19%), or TDF monotherapy (1

209 The inclusion of lamivudine or emtricitabine in cART did not influence th

210 zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapi

211 400 mg and ritonavir 100 mg twice daily and lamivudine or emtricitabine plus another nucleoside reve

212 Clinical trials of RPV administered with lamivudine or emtricitabine showed the emergence of E138

213 out baseline resistance (N = 4740) initiated lamivudine or emtricitabine with efavirenz/tenofovir or

214 apy with tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside rever

215 ine, stavudine, tenofovir, or abacavir, plus lamivudine or emtricitabine) with either efavirenz or ne

216 e combinations were studied (all paired with lamivudine or emtricitabine): efavirenz (EFV) plus zidov

217 GSS (gGSS), defined as the combined GSS for lamivudine or emtricitabine, abacavir, zidovudine, stavu

218 , combined with zidovudine or tenofovir plus lamivudine or emtricitabine.

219 e of them underwent pre-emptive therapy with lamivudine or other antiviral drugs and no one showed ep

220 Compared to control, lamivudine or telbivudine improved maternal HBV DNA supp

221 did not differ according to whether abacavir-lamivudine or tenofovir DF-emtricitabine was also given.

222 r antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine.

223 given with with placebo-controlled abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtrici

224 nitial therapy for HIV-1 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtrici

225 se transcriptase inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabin

226 fumarate plus emtricitabine, zidovudine plus lamivudine, or abacavir plus lamivudine).

227 on period on oral cabotegravir plus abacavir-lamivudine, patients with viral suppression (plasma HIV-

228 gestation to lopinavir/ritonavir/zidovudine/lamivudine (PI group) or abacavir/zidovudine/lamivudine

229 trial of initial therapy with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted l

230 lated LT between 1998 and 2010 and receiving lamivudine plus HBIg were followed for a median of 77 mo

231 y data, tenofovir-emtricitabine or tenofovir-lamivudine plus nevirapine is used in many resource-cons

232 comes than did treatment with zidovudine and lamivudine plus nevirapine.

233 regimens included stavudine/zidovudine plus lamivudine plus nevirapine/efavirenz.

234 viral treatment consisting of zidovudine and lamivudine plus ritonavir-boosted lopinavir resulted in

235 ibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a nonnucleoside reverse transcriptase i

236 tenofovir alafenamide, abacavir/dolutegravir/lamivudine, raltegravir, rilpivirine, atazanavir/ritonav

237 with hepatitis B immunoglobulin (HBIg) plus lamivudine reduces the risk of hepatitis B virus (HBV) r

238 tis B patients but it is not as effective in lamivudine-refractory patients.

239 al therapy with lopinavir and ritonavir plus lamivudine regimen warrants further clinical research an

240 61.5% vs 25.0%, P = .03), and development of lamivudine resistance (31.3% vs 12.2%; P < .0001).

241 o of these substitutions are associated with lamivudine resistance (LVDr) in the tyrosine-methionine-

242 he emergence of HBV DNA mutations conferring lamivudine resistance (rtM204I/V) were determined.

243 to many sites of HBV proteins confirms that lamivudine resistance is a complex trait encoded by the

244 with levels of HBV DNA >/=3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or rever

245 rbations of hepatitis, HBeAg seroconversion, lamivudine resistance, and liver disease-related death t

246 aa changes, other than those associated with lamivudine resistance, were observed in patients with pe

247 re observed, 5 of which were associated with lamivudine resistance.

248 variant, indicating the convergent nature of lamivudine resistance.

249 from 5 NRTI-treated patients, including the lamivudine-resistance mutation V173L (in 5 samples), the

250 activity against both adefovir-resistant and lamivudine-resistant double (rtL180M/rtM204V) mutants as

251 t against both adefovir-resistant as well as lamivudine-resistant double (rtL180M/rtM204V) mutants.

252 oside analogs, the more rapid development of lamivudine-resistant HBV in patients who are HIV-positiv

253 sistance profile and is fully active against lamivudine-resistant HBV.

254 disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection,

255 and effective for treatment of patients with lamivudine-resistant, chronic HBV infection.

256 girls (but not boys) exposed in utero to ZDV/lamivudine/ritonavir-boosted lopinavir (LPV/r) had a hig

257 nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not perfor

258 The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir.

259 Exposure to lamivudine and to lamivudine-stavudine were also associated with an increa

260 erivatives, key intermediates for asymmetric lamivudine synthesis, was elucidated.

261 n, except with a different film colour), and lamivudine tablets and tenofovir disoproxil fumarate and

262 (ART) with either tenofovir-emtricitabine or lamivudine (tenofovir group) or zidovudine-lamivudine (z

263 ed with high-level resistance to zidovudine, lamivudine, tenofovir, or abacavir.

264 er in patients randomly assigned to abacavir-lamivudine than in those assigned to tenofovir DF-emtric

265 s of efavirenz that included zidovudine plus lamivudine than those including tenofovir plus emtricita

266 ceive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibit

267 llimeter received nevirapine plus zidovudine-lamivudine (the observational group).

268 roup) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34

269 Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricita

270 However, HBIg is expensive, and lamivudine therapy is limited by drug resistance.

271 r 18 years of age (hazard ratio = 2.46), and lamivudine therapy prior to HBeAg seroconversion (hazard

272 Lamivudine therapy selects for the M184V mutation.

273 achieve protective HBV immunity or lifelong lamivudine therapy should prevent posttransplant HBV inf

274 ar tolerability profile of dolutegravir plus lamivudine to a guideline-recommended three-drug regimen

275 eAg-negative hepatitis increased to 2.64% in lamivudine-treated subjects but did not increase in thos

276 status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years).

277 The role of specific genotypes and prior lamivudine treatment in the delayed response to TDF warr

278 After a median of 45 months of lamivudine treatment, HIV-1 RNA and HBV DNA were detecta

279 Despite widespread use, however, lamivudine triphosphate (3TC-TP) exposure in the FGT is

280 ies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patient

281 Pegylated interferon-alpha2a combined with lamivudine versus lamivudine improved HBeAg loss (1 RCT;

282 troviral Design Encompassing Lopinavir/r and Lamivudine vs LPV/r based standard therapy) is a 48 week

283 The use of lamivudine was associated with more virological failure

284 In contrast, removal of acyclovir and lamivudine was mainly attributable to slower microbial p

285 Lamivudine was the first approved agent, but its use lea

286 riptase inhibitors, especially stavudine and lamivudine, was associated with possible mitochondrial d

287 Efavirenz (600 mg/d) and stavudine plus lamivudine were administered in addition to standard ant

288 eceiving daily tenofovir disoproxil fumarate/lamivudine were recruited.

289 of lamivudine and for settings where generic lamivudine will be available.

290 EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFLD were randomized 1:1 to switch from

291 r to oral therapy with dolutegravir-abacavir-lamivudine with regard to maintaining HIV-1 suppression.

292 scriptase inhibitors (2NRTI, mainly abacavir+lamivudine) with a non-nucleoside reverse transcriptase

293 non-inferior to dolutegravir, abacavir, and lamivudine, with 276 (88%) of 314 participants in the bi

294 to coformulated dolutegravir, abacavir, and lamivudine, with no treatment-emergent resistance.

295 drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside resistance including type 2

296 r lamivudine (tenofovir group) or zidovudine-lamivudine (zidovudine group).

297 Lamivudine, zidovudine, emtricitabine, and tenofovir had

298 l antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus did

299 mized to 3 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (ataza

300 labor and were randomly assigned to receive lamivudine/zidovudine, emtricitabine/tenofovir, or lopin